

Edgar Filing: PROVECTUS PHARMACEUTICALS INC - Form 8-K

PROVECTUS PHARMACEUTICALS INC
Form 8-K
July 28, 2004

United States Securities and Exchange Commission
Washington, DC 20549

Form 8-K

Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 28, 2004

Provectus Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)

Nevada	0-9410	90-0031917
-----	-----	-----
(State or Other Jurisdiction of Incorporation or Organization)	(Commission File Number)	(I.R.S. Employer Identification Number)

7327 Oak Ridge Highway, Suite A, Knoxville, Tennessee	37931
-----	-----
(Address of Principal Executive Offices)	(Zip Code)

Registrant's telephone number, including area code: 865/769-4011

(Former Name or Former Address, if Changed Since Last Report)

Item 5. Other Events

On July 28, 2004, Provectus Pharmaceuticals, Inc. announced that it had received a \$20.75 million financial commitment from Cornell Capital Partners, LP. A copy of the entire press release is incorporated herein by reference and attached to this report as an exhibit.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

(c) Exhibits.

99.1 Press Release dated July 29, 2004

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Provectus Pharmaceuticals, Inc.

Edgar Filing: PROVECTUS PHARMACEUTICALS INC - Form 8-K

Dated: July 28, 2004

By: /s/ H. Craig Dees

H. Craig Dees, Ph.D.
Chief Executive Officer